Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

A year after the failure of an idiopathic pulmonary fibrosis candidate sent Galecto on a search for salvation, the ...

Ceribell, the maker of a portable, brain-reading headset for emergency seizure care, aims to go public on the Nasdaq through ...

A startup that aims to deliver a blood test to identify a biomarker linked with a specific subtype of autism—and then ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

Psyence Biomedical has walked away from its planned acquisition of fellow Canadian psilocybin-based biotech Clairvoyant ...

The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. | The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists ...

Pentixapharm has brought in almost 20 million euros ($22 million) from an IPO, with the German biotech earmarking the ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...